Universe›Health Care›Pharmaceuticals
Observatory · observe first

Pharmaceuticals

Pharmaceuticals is gaining market weight. Lost weight for 1 consecutive month.

Historical time machine
Historical observation
20182026
AcceleratingConcentrated

Most of this industry's gains came from a few companies.

Universe weight
5.60%
$0.91T
12-month change
+0.10 pp
6-month change
+0.10 pp
3-month change
+0.10 pp
Company participation
67%
above their 6M weight average

Where did the weight change come from?

12-month contribution in universe percentage points · contributions add to the industry change

Company attribution
Pfizer →+0.076 pp
All other companies+0.024 pp
Industry total+0.100 pp

The three largest same-direction contributors explain 85% of gross gains. Opposing contributions can make an individual company’s change larger than the industry’s net change.

How has it moved through history?

Share of matched S&P 500 members

Jan 2018 – Apr 2018 · market weight (%)

5.55.65.62018

Relative performance

Industry return versus ACWI · no future data shown

1001011022018

Is participation broad or concentrated?

Actual constituent counts at this date, not the legacy synthetic breadth proxy

Above their 3M universe-weight average67%
Above their 6M universe-weight average67%
Above their 12M universe-weight average0%
Top 5 share of current industry market cap95.6%

This is size concentration, not contribution to the 12-month change. The attribution above measures the latter.

Evidence can disagree

Independent dimensions · no combined score or bullish/bearish verdict

Allocation · 12M+0.10 pp
Relative strength · 12M+1.2%
Price index return · 12M-4.4%
Earnings revisions · unavailable0.0
Allocation gained weight while relative performance rose. At least half of constituents are above their 6M weight average. These observations need not agree.
Other evidence and availability

Valuation data: unavailable; shown as zero placeholder.

Attention data: unavailable; shown as zero placeholder.

Actual fund flows: unavailable. No ETF, mutual-fund or institutional flow feed is connected.

Volume / turnover: unavailable in this dataset.

Follow the contribution to individual companies

Sorted by absolute 12-month weight contribution, not investment merit

CompanySub-industryCountryUniverse weight12M contribution12M price returnRevisions
Pfizer →
PFE
PharmaceuticalsUnited States1.271%+0.076 pp-0.2%0.0
Bristol Myers Squibb →
BMY
PharmaceuticalsUnited States0.524%-0.061 pp-16.2%0.0
Merck & Co. →
MRK
PharmaceuticalsUnited States0.931%+0.052 pp+0.2%0.0
Zoetis →
ZTS
PharmaceuticalsUnited States0.249%+0.036 pp+9.0%0.0
Johnson & Johnson →
JNJ
PharmaceuticalsUnited States2.085%-0.032 pp-7.9%0.0
Lilly (Eli) →
LLY
PharmaceuticalsUnited States0.541%+0.029 pp+0.3%0.0
Underlying monthly industry observations
MonthWeight1M change3M change6M change12M changeRelative return · 12M
Apr 20185.600%-0.001 pp+0.100 pp+0.100 pp+0.100 pp+1.2%
Mar 20185.601%+0.060 pp+0.101 pp+0.101 pp+0.101 pp+1.6%
Feb 20185.542%+0.042 pp+0.042 pp+0.042 pp+0.042 pp+1.2%
Jan 20185.500%+0.000 pp+0.000 pp+0.000 pp+0.000 pp+0.0%
How are these descriptive states defined?

Gaining / losing: 12-month weight change above +0.005pp / below −0.005pp. Direction and speed are separate dimensions, not mutually exclusive recommendations.

Accelerating / slowing: compare the most recent 3M change with the preceding 3M change. Accelerating means a positive change speeds up by >0.02pp. Slowing means the magnitude of movement declines by >0.02pp. A falling industry can also slow.

Reversing: the last two 3M changes have opposite signs, outside a ±0.005pp tolerance. Persistence counts consecutive same-direction monthly changes.

Broad / concentrated: company attribution, not a market-cap concentration shortcut. Concentrated means the three largest same-direction contributors account for ≥70% of gross same-direction changes; otherwise broad requires ≥60% of constituents moving with the industry. Other cases are mixed.

Weights use matched S&P 500 members’ market-cap estimates, based on SEC-reported shares available by each month-end and monthly closing prices. Companies without a matched price or share record are omitted, so the denominator is the matched sample rather than every index member. These are not official float-adjusted S&P weights. Flow is not measured.